Large genetic study uncovers new Alzheimer’s drug targets

A major analysis of genetic data has linked 127 gene locations to Alzheimer’s disease, including 48 previously unidentified ones. Researchers also flagged several genes as promising drug targets and highlighted changes in immune and nerve cells.

The study examined genome information from nearly 110,000 people diagnosed with Alzheimer’s and 74,000 others who had a parent with the condition. It compared these against data from 2.6 million people without the disease. This effort identified 127 associated gene locations, 48 of which are new findings.

관련 기사

Illustration of mutated blood cells entering the brain through the blood-brain barrier, linked to Alzheimer's pathology.
AI에 의해 생성된 이미지

Study finds blood-cancer-linked mutations in brain immune cells tied to Alzheimer’s pathology

AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨

Researchers at Boston Children’s Hospital report that mutations commonly associated with clonal blood-cell expansion and some blood cancers were enriched in microglia-like immune cells in Alzheimer’s brains and were also detectable in matched blood samples. The Cell study proposes that age- or injury-related weakening of the blood-brain barrier could allow mutated blood immune cells to enter the brain, potentially amplifying inflammation and contributing to neurodegeneration.

Japanese researchers have identified a new seed of the amyloid beta protein. The discovery could lead to early-stage therapy for the neurodegenerative disease.

AI에 의해 보고됨

Scientists at the University of Southern California have found experimental compounds that may reduce harmful brain inflammation associated with Alzheimer’s disease. The work focuses on the enzyme cPLA2 and people who carry the high-risk APOE4 gene.

A new blood test can show Alzheimer risk up to 20 years before symptoms. Private clinics offer the test to healthy people, drawing criticism from doctors.

이 웹사이트는 쿠키를 사용합니다

사이트를 개선하기 위해 분석을 위한 쿠키를 사용합니다. 자세한 내용은 개인정보 보호 정책을 읽으세요.
거부